An important advancement with human induced pluripotent stem cells (iPSCs) was announced February 2021. The GMP iPSC cell line ND50039 distributed by Sampled as part of the NINDS Repository was approved for use in a clinical trial in Germany. This is the first time that engineered heart muscle (EHM) from iPSCs will be used to treat patients with heart failure. See the full announcement here.